Research Analysts Set Expectations for OCUL FY2026 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Ocular Therapeutix in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst Y. Chen anticipates that the biopharmaceutical company will post earnings of ($1.46) per share for the year. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Several other research analysts have also weighed in on the company. Needham & Company LLC lowered their price objective on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research report on Tuesday, March 4th. Royal Bank of Canada began coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective for the company. Finally, William Blair began coverage on Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.25.

Ocular Therapeutix Price Performance

Shares of OCUL stock traded up $0.34 during trading hours on Wednesday, reaching $7.40. The company had a trading volume of 679,901 shares, compared to its average volume of 1,416,938. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The stock has a fifty day moving average of $7.46 and a 200-day moving average of $8.25. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -5.59 and a beta of 1.51. Ocular Therapeutix has a 12-month low of $4.79 and a 12-month high of $11.78.

Institutional Trading of Ocular Therapeutix

Hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in Ocular Therapeutix in the fourth quarter valued at $28,000. Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix in the 4th quarter valued at about $43,000. AlphaQuest LLC acquired a new position in Ocular Therapeutix in the 4th quarter valued at about $53,000. GAMMA Investing LLC increased its position in Ocular Therapeutix by 6,760.0% in the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 8,112 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Ocular Therapeutix by 2,045.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 8,446 shares during the period. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Pravin Dugel sold 21,475 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.50% of the stock is owned by corporate insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.